首页 | 本学科首页   官方微博 | 高级检索  
检索        


Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective
Institution:1. Resident in Internal Medicine, Mayo School of Graduate Medical Education, Rochester, MN;2. Advisor to residents and Consultant in Cardiovascular Diseases, Mayo Clinic, Rochester, MN;1. Division of Psychiatry, University College London, London W1T 7NF, UK;1. Alzheimer''s Disease and Other Cognitive Disorders Unit, Hospital Clínic, Institut d''Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain;2. Barcelona βeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain;3. Department of Psychology, Brooklyn College and The Graduate Center of CUNY, Brooklyn, NY, USA;4. Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA;5. Center for Alzheimer Research and Treatment, Brigham and Women''s Hosptial and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;6. Florey Institute of Neuroscience and Mental Health, Melbourne, Australia;7. Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia;8. Institute of Memory and Alzheimer''s Disease and Brain and Spine Institute (ICM) Pitié Salpetriere University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris, France;9. Department of Psychiatry, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia;10. Institute for Stroke and Dementia Research, Klinikum der Universität München Ludwig-Maximilians-Universität LMU, Munich, Germany;11. AXA Research Fund & UPMC Chair, Paris, France;12. Department of Psychiatry and Psychotherapy, University Medical Center Freiburg, Freiburg, Germany;13. Center of Geriatrics and Gerontology, University Medical Center Freiburg, Freiburg, Germany;14. Department of Psychiatry, New York University Langone Medical Center, New York, NY, USA;15. Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA;p. Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA;q. Department of Neurology, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands;r. Department of Epidemiology and Biostatistics, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands;s. Neuroscience Campus Amsterdam, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands;t. Department of Psychology, University of Victoria, Victoria, BC, Canada;u. Institute on Aging and Lifelong Health, University of Victoria, Victoria, BC, Canada;v. Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA;w. Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany;x. German Center for Neurodegenerative Disorders (DZNE), Bonn-Cologne, Germany;y. Department of Psychiatry, University Hospital Cologne, Medical Faculty, Cologne, Germany;1. VA Greater Los Angeles Healthcare System, West LA VA, Los Angeles, CA, USA;2. Dept. of Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;3. University of Cincinnati College of Medicine, Department of Neurology, Cincinnati, OH, USA;1. Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, People''s Republic of China;2. Department of Computer Science, University of Otago, Dunedin, New Zealand;3. Department of Neurology, Fu Xing Hospital, Capital Medical University, Beijing, People''s Republic of China;4. Evidence-Based Medicine Center, Xuan Wu Hospital, Capital Medical University, Beijing, People''s Republic of China;5. Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong SAR, People''s Republic of China;6. McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada;7. Department of Geriatrics, Guangzhou Brain Hospital, Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong Province, People''s Republic of China;8. Department of Neurology, Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou Province, People''s Republic of China;9. Department of Neurology, Third Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan Province, People''s Republic of China;10. Department of Neurology, First Hospital of Jilin University, Changchun, Jinlin Province, People''s Republic of China;11. Department of Neurology, Fourth Hospital of Jilin University, Changchun, Jinlin Province, People''s Republic of China;12. Department of Neurology, Beijing Geriatric Hospital, Beijing, People''s Republic of China;13. National Center for Chronic and Noncommunicable Disease Control and Prevention, Beijing, People''s Republic of China;14. Department of Neurology, Tongren Hospital, Capital Medical University, Beijing, People''s Republic of China
Abstract:Mild cognitive impairment and mild dementia are common problems in the elderly. Primary care physicians are the first point of contact for most patients with these disorders and should be familiar with their diagnosis, prognosis, and management. Both mild cognitive impairment and mild dementia are characterized by objective evidence of cognitive impairment. The main distinctions between mild cognitive impairment and mild dementia are that in the latter, more than one cognitive domain is invariably involved and substantial interference with daily life is evident. The diagnosis of mild cognitive impairment and mild dementia is based mainly on the history and cognitive examination. The prognosis for mild cognitive impairment and mild dementia is an important motivation for diagnosis because in both, there is a heightened risk for further cognitive decline. The etiology of mild cognitive impairment and mild dementia can often be established through the clinical examination, although imaging and other laboratory tests may also contribute. Although Alzheimer disease is the most common cause of both, cerebrovascular disease and Lewy body disease make important contributions. Pharmacological treatments are of modest value in mild dementia due to Alzheimer disease, and there are no approved pharmacological treatments for mild cognitive impairment of any etiology. Nonetheless, new-onset cognitive impairment is a worrisome symptom to patients and families that demands answers and advice. If a patient is having difficulties managing medications, finances, or transportation independently, diagnosis and intervention are necessary to ensure the health and safety of the patient.
Keywords:AD"}  {"#name":"keyword"  "$":{"id":"kwrd0015"}  "$$":[{"#name":"text"  "_":"Alzheimer disease  CT"}  {"#name":"keyword"  "$":{"id":"kwrd0025"}  "$$":[{"#name":"text"  "_":"computed tomography  MCI"}  {"#name":"keyword"  "$":{"id":"kwrd0035"}  "$$":[{"#name":"text"  "_":"mild cognitive impairment  MRI"}  {"#name":"keyword"  "$":{"id":"kwrd0045"}  "$$":[{"#name":"text"  "_":"magnetic resonance imaging
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号